Minichromosome maintenance (MCM) proteins 2-7 are important in DNA replication licensing. Functional roles beyond licensing are speculated. In addition, significances in medulloblastoma (MB) remain unclear. In this study, we showed the frequent deregulation of MCM2 and MCM3 expression in 7 MB cell lines and 31 clinical samples. Moreover, DAOY and ONS76 and the clinical samples expressed elevated MCM7 transcripts with genomic gain of the gene. Immunopositivity restricted to tumor cells was found in 41, 37 and 53 out of 73 MB cases for MCM2, MCM3 and MCM7, respectively. High-MCM3 expression was associated with poor prognosis. Knockdowns of these MCMs significantly inhibited anchorage-dependent and -independent MB cell growth. The inhibition of MCM3 expression by small interfering RNA knockdown was related to G1 arrest with reduced cyclin A expression, whereas the MCM2-and MCM7-knocked-down cells arrested at G2/M with increased cyclin A expression. Interestingly, we demonstrated the links of these MCMs with cell migration and invasion using wound-healing and Transwell migration/invasion assays. Exogenous overexpression of MCM2, MCM3 and MCM7 increased anchorage-independent cell growth, and also cell migration and invasion capabilities in MB cells. The knockdown reduced the number of filopodial cells and the cells with intense stress fibers by blocking cdc42 and Rho activation. Taken together, deregulation of MCM2, MCM3 and MCM7 expression might be involved in MB tumorigenesis and we revealed undefined roles of these MCMs in control of MB cell migration and invasion.
Introduction
Medulloblastoma (MB) is the most common malignant tumor of the central nervous system in children, which is derived from primitive, pluripotent, neuroepithelial stem cells in the cerebellum as a result of cumulative genetic and epigenetic alterations at multiple genes that control growth, migration and invasion. Previously, we and others used conventional and array-based comparative genomic hybridization (CGH) to study MB genome and demonstrated various recurrent chromosomal aberrations, including gain of chromosome 7 and chromosomal amplification in 7q, in MB (Reardon et al., 1997; Avet-Loiseau et al., 1999; Nicholson et al., 1999; Nishizaki et al., 1999; Bayani et al., 2000; Giangaspero et al., 2000; Gilhuis et al., 2000; Eberhart et al., 2002; Tong et al., 2004; Hui et al., 2005; De Bortoli et al., 2006; Rossi et al., 2006) .
In a normal cell, chromosomal DNA is precisely duplicated with replication forks initiated at replication origins scattered throughout the genome. Precise chromosomal duplication is maintained by a replication-licensing system. The system prevents abnormal activation of replication origins; insufficient firing of the origins leads to DNA strand breaks and gross chromosomal rearrangements, whereas over-firing results in DNA amplification (Bailis and Forsburg, 2004; Lei, 2005; Blow and Gillespie, 2008) . Origin licensing occurs before S phase and at early G1 phase by loading the minichromosome maintenance (MCM) protein complex, which is composed of six MCM proteins (MCM2-MCM7), onto DNA at the replication origins (Bailis and Forsburg, 2004; Lei, 2005; Blow and Gillespie, 2008) . It was reported that deregulation of MCM expression disrupted genetic stability and was associated with DNA damage in yeast. In this regard, inappropriate expression of MCM subunits, predominantly overexpression, was shown in various human premalignant dysplastic lesions and cancers (Bailis and Forsburg, 2004; Lei, 2005; Blow and Gillespie, 2008) .
Because of a large excess of MCM complexes over the number of active replication origins (Burkhart et al., 1995; Todorov et al., 1995) , it was speculated that MCMs might not be simply involved in DNA replication licensing, but may also have roles in other cellular functions. This speculation was supported by two observations referred to as the 'MCM paradox': at least in yeast, Xenopus and Drosophila, reduced concentration of MCM proteins does not impair DNA replication (Lei et al., 1996; Oehlmann et al., 2004; Crevel et al., 2007) and the majority of MCM complexes do not localize to the sites of DNA synthesis in mammalian cells (Hyrien et al., 2003; Takahashi et al., 2005) . In addition, different MCMs individually interact with many proteins that are involved in various cellular functions (Forsburg, 2004) , prompting to investigate the additional roles of MCMs beyond replication licensing.
In this study, we investigated the significance of MCMs in MB and demonstrated a genetic alteration of MCM7 and deregulation of MCM2, MCM3 and MCM7 expression in both MB cell lines and clinical samples. For clinical relevance, high expression of MCM3 in MB was associated with poor patient's survival. Results of small interfering RNA (siRNA) knockdown and overexpression studies implicated the involvement of deregulated MCM2, MCM3 and MCM7 in controls of the anchorage-dependent and -independent MB cell growth and also the links between these MCMs and cell migration and invasion in MB, probably through modulations of filopodia and stress fiber formation with cdc42 and Rho activation.
Results

MCM2-7 mRNA expression in MB
Analysis of the publicly available microarray data indicated a significant increase of MCM2, MCM3, MCM5 and MCM7 transcripts in 60 MB samples compared with the normal cerebellar samples ( Figure 1a ). The transcript levels of MCM2 and MCM3 were significantly associated (Po0.001, Rs ¼ 0.523). Results of Kaplan-Meier survival analysis with log-rank test showed that patients with a high level of MCM3 transcripts in tumors (upper three quartiles) had poorer survival (Figure 1b ), but not for other MCMs (Supplementary Figure S1 ). No significant difference in their expressions was found between classic and desmoplastic MB. Consistent with the microarray data, MCM2 and MCM3 mRNA expression were generally increased in seven MB cell lines. Comparable levels for MCM4, MCM5 and MCM6 were found when compared with five normal cerebellar samples by real-time reverse transcription-PCR analysis (Figure 1c) . Even though MCM7 expression in MB cell lines generally showed no difference from normal cerebellum (NC), DAOY and ONS76 expressed a very high level of MCM7 transcripts. Regarding the clinical samples, we found overexpression (4twofold increase) of MCM2 mRNA in 13 out of 23 (56.5%) pediatric and 6 out of 8 (75%) adult MB cases, whereas 18 (78.3%) pediatric and 6 (75%) adult MB cases expressed elevated mRNA levels of MCM3 (Figure 1d ). In this cohort, a high level of MCM3 transcripts also was associated with poor overall survival (Figures 1e and f) . Similar to the findings from DNA microarray data, MCM2 and MCM3 expression were highly correlated (P ¼ 2.5 Â 10
À5
, Rs ¼ 0.7703). MCM7 expression was overexpressed in 21 (91.3%) pediatric and all the 8 (100%) adult MB cases ( Figure 1d ) and was correlated with the expression of both MCM2 (P ¼ 1.6 Â 10 À4 , Rs ¼ 0.6895) and MCM3 (P ¼ 5.8 Â 10
, Rs ¼ 0.734). There was no statistically significant difference in the expression of MCM mRNAs between classic and desmoplastic types of MB.
Alteration of genomic region with MCM7 gene in MB Analysis of Agilent whole human genome 44K CGH microarray data of four MB cell lines (DAOY, ONS76, D283 and D341) and eight clinical samples (Z-score algorithm with 4 as threshold level for detection of chromosomal aberration and 2 Mb as window size) revealed a number of recurrent chromosomal gains and losses in MB genome. Focusing on the chromosomal regions wherein six MCM genes are located, we found a copy number gain of MCM7 gene in DAOY and ONS76, as well as five clinical MB samples (Figures 2a  and b ), but no recurrent chromosomal aberration in the regions wherein other MCMs are located (Figure 2b ). The frequency of this genomic gain of MCM7 gene was further investigated in 33 clinical MB samples using fluorescence in situ hybridization with a specific probe targeting 7q22.1 (MCM7 gene) and a reference probe targeting 7p14.1 (Figure 2c ). In all, 24 (73%) MB samples showed concordant signal increase for both 7q22.1 and 7p14.1 probes, suggesting whole chromosome 7 gain in these tumors as previously reported (Reardon et al., 1997; Avet-Loiseau et al., 1999; Nicholson et al., 1999; Nishizaki et al., 1999; Bayani et al., 2000; Gilhuis et al., 2000; Eberhart et al., 2002; Tong et al., 2004; Hui et al., 2005; De Bortoli et al., Figure 1 MCM2-7 mRNA expression in MB. (a) A dot plot of the normalized microarray data for MCM2-7 expression in normal cerebellum (NC; m) and MB ('). Affymetrix DNA microarray data were obtained from Human Gene Expression Index and Cancer Program Data Set at Broad Institute were normalized and were analyzed by Mann-Whitney U-test to compare the MCM2-7 expression between NC and MB. (b) Kaplan-Meier survival curves with log-rank test for MB patients with low and high MCM3 expression and the censored patients are shown with solid ovals and crosses, respectively. (c, d) A dot plot of quantitative reverse transcription-PCR (RT-PCR) results for MCM2-7 mRNA expression in seven MB cell lines (c) and clinical MB (d) versus NC samples. Relative fold changes of MCM2-7 mRNAs to NC in MB cell lines and clinical MB samples are presented. The MannWhitney U-test was conducted to compare the levels of MCM2-7 mRNA between NC and MB cell lines/clinical samples. Each sample was subjected to RT-PCR in triplicate (n ¼ 3). The P-values are adjusted by Benjamini and Hochberg correction. Bars represent means. (e, f) Kaplan-Meier overall survival curves (e) and disease-free survival curves (f) with log-rank test for MB patients with low and high MCM2, MCM3, and MCM7 mRNA expression determined by RT-PCR. The censored patients are shown with solid ovals for those expressing low levels of MCM mRNAs and crosses for those expressing high levels of the mRNAs. Ch6: 30, 514, 440, .31]
Chromosomal regions with genomic gains in MB
MCM2
MCM3
MCM4
Ch8: 49,036,047 -49,052,621 no recurrent genomic gain in chromosome 8
Genomic aberrations in chromosome 7
No genomic change in chromosome 7
MCM5
MCM6 no recurrent genomic gain in chromosome 2
MCM7
MCM genes MCM gene locations Ch3: 128, 799, 823, 966 Ch6: 52, 236, 258, 171 Ch22: 34, 126, 150, 494 Ch2: 136, 313, 350 (Todorov et al., 1994; Endl et al., 2001; Williams and Stoeber, 2007) . In our cohort, there were 23 (32%), 21 (29%) and 33 (45%) MB cases with MCM2, MCM3 and MCM7 labeling indexes more than fivefold of the Ki67 index. Regarding the pathological significance, there was no association of these MCM proteins and Ki67 expression with MB histological subtypes. Results of Kaplan-Meier survival analysis with log-rank test on 20 pediatric patients indicated that positive MCM3 immunostaining in MB tissue was associated with poor overall survival ( Figure 3c ) and also with disease-free survival ( Figure 3d ), but not the others. In our cohort, patient's age, gender and histological subtypes showed no prognostic significance in line with previous reports (Giordana et al., 1998; Polkinghorn and Tarbell, 2007) (Supplementary Table S2 ). Flow cytometry data indicated that knockdowns of MCM2 or MCM7 in DAOY cells for 24 h induced G2/M arrest (that is, low ratio of G0/G1 to G2/M cell populations). They further increased the arrests and eventually induced prominent apoptosis (that is, accumulation of sub-G0/G1 cell population and increase of Annexin V-stained cells) after 48 h. In contrast, the MCM3-knocked-down cells arrested at G1 phase after 24 and 48 h and underwent apoptosis after 48 h ( Figures  4b and c) . The level of cyclin A was significantly reduced in the MCM3-knocked-down cells, but increased for MCM2 or MCM7 knockdowns. There was no change in the levels of cyclins B and D (Figure 4d ). In addition, the knockdowns inhibited the anchorageindependent cell growth of both MB cell lines. For DAOY, knockdown of MCM2, MCM3 and MCM7 induced B60, 40 and 45% inhibition of soft agar cell growth, respectively ( Figure 4e ). Similar cell growth inhibitions were also observed in ONS76 cells (Supplementary Figure S3 ). In contrast, overexpression of MCM2/MCM3/MCM7 increased the growth of HEK293 cells in soft agar (Supplementary Figures S4B and S5) .
siRNA knockdown of MCM2, MCM3 and MCM7 reduced MB cell migration and invasion Using wound-healing assay, knockdown of MCM2, MCM3 and MCM7 in DAOY reduced the migration capacity into the wounds, whereas control cells (that is, cells with transfection reagent alone and cells with negative control siRNA) were able to almost completely fill the wound after 26 h ( Figure 5a ). The inhibitory effects of the knockdowns on cell migration and invasion were also demonstrated by Transwell migration and invasion assays (Corning, NY, USA), as the cell population that migrated through the membrane pores or pre-coated matrigel to the undersurface of the upper chamber significantly decreased (Figures 5b and c) . The involvement of these MCMs in regulation of cell migration/invasion was confirmed by exogenous overexpression of MCM2/MCM3/MCM7 in D384 and also in HEK293. By Transwell migration/invasion Figure 2 Genetic alteration of MCM7 gene in MB. (a) Agilent array CGH 44K data for chromosome 7 of MB cell lines and clinical samples were analyzed to identify chromosomal regions with genomic gains (red colored). Genomic DNAs were extracted from four MB cell lines (D283, DAOY, ONS76 and D341) and eight primary MB samples. Purities and quantities of the DNA samples were determined using Thermo Scientific NanoDrop ND1000 spectrophotometer. The samples and gender-matched reference DNA were labeled with Cy3-and Cy5-dUTP, respectively, using random priming and hybridized onto Agilent whole human genome 44K CGH microarray (Agilent Technologies) in accordance with the manufacturer's protocol. The slides were scanned with Agilent DNA microarray scanner (Agilent) and the captured images were analyzed using Agilent Feature Extraction software 8.1 by applying linear and Lowess normalization methods and local background subtraction. The data were visualized and statistically analyzed using CGH Analytics 3.2.32 program (Agilent) with Z-score algorithm for detection of chromosomal aberrations. (b) Chromosomal regions with recurrent genomic gains in MB from the results of array CGH data and the regions harboring MCM2-7 genes were tabulated. It indicated that the chromosomal regions with recurrent genomic gains in MB harbor MCM7 gene, but no genetic alteration in chromosomal regions where other MCM genes are located. (c) Results of fluorescence in situ hybridization (FISH) analysis of 7q22.1 (MCM7) in clinical MB samples. Representative micrographs with fluorescence microscopy for 7q22.1 target probe (orange) and 7p14.1 (green) are presented. Six representative MB clinical samples with cells showed no genomic change in chromosome 7 (left upper and lower), whole chromosome 7 gain (middle upper and lower) or preferential genomic gain of 7q22.1 with no change of 7p14.1 (right upper and lower). High-molecular-weight DNA isolated from BAC clones was labeled with Spectrum-Orange-dUTP (Vysis) for BAC RP11-143F21 (target probe) and with Spectrum-Green-dUTP for BAC clone RP11-111K18 (reference probe) by nick translation. Chromosomal locations of the probes were validated by FISH analysis of metaphase spreads prepared from peripheral blood of normal healthy individuals. The FISH probes were hybridized onto the pepsin-digested tissue sections overnight and the sections were counterstained with 4 0 ,6-diamidino-2-phenylindole. The fluorescence signals were detected and imaged using a Zeiss fluorescence microscope (Carl Zeiss, Jena, Germany) with a triple band pass filter set for recognition of Spectrum-Orange and Spectrum-Green probes. Involvement of MCM2, MCM3 and MCM7 in regulation of filopodia and stress fiber formation in MB cells through cdc42 and Rho activation, respectively DAOY with MCM2/MCM3/MCM7 knockdown showed defects in formation of filopodia with reduced number and length of filamentous-actin (F-actin)-rich spiky protrusions, and also in formation of stress fibers, whereas the controls showed abundance of long filopodia on the cell surfaces and intense stress fibers in the cytoplasm (Figure 7a) . Quantitatively, the knockdowns significantly reduced the percentages of filopodial cells and also the percentages of cells with intense stress fibers ( Figure 7b ). As activation of cdc42 leads to formation of filopodia and activation of Rho for formation of stress fibers (Nobes and Hall, 1995) , the knockdowns of these MCMs resulted in significant inhibition of both cdc42 and Rho activation. The GTPbound (active form) cdc42 and also GTP-bound Rho were significantly reduced in the MCM-knocked-down cells, with no change in the levels of total cdc42 and Rho (Figure 7c ).
Discussion
Currently, the precise functional roles of MCM proteins remain to be determined. It was demonstrated that MCMs are far more abundant than replication origins (Burkhart et al., 1995; Todorov et al., 1995) , suggesting that these proteins might have functions in addition to replication licensing. Emerging evidence indicated that MCMs are also involved in transcription by either association with the carboxy-terminal domain of RNA polymerase II such as MCM2, MCM3 and MCM7 (Yankulov et al., 1999) or association with specific transcription factors such as MCM3-MCM5 complex with STAT1a (DaFonseca et al., 2001 ) and MCM7 with MADS-box transcription factor MCM1 (Fitch et al., 2003) . Increased expression of MCM7 promotes tumor formation, progression and malignant conversion of chemical-induced skin cancer (Honeycutt et al., 2006) . Ecotopic expression of MCM3 in HEK293 induced tumorigenicity to form tumors in nude mice (Ha et al., 2004) . In this study, we demonstrated that siRNA knockdowns of MCM2, MCM3 and MCM7 significantly reduced MB cell migration and invasion capabilities, with inhibition of cdc42 and Rho activations and filipodia and stress fiber formation in the cells. Overexpression of these MCMs resulted in increase of MB cell migration and invasion capabilities and growth in soft agar. These findings imply the undefined roles of these MCMs in tumorigenesis of MB. However, the manner in which these MCM 'nuclear' proteins regulate F-actin formation in cytoplasm to mediate the cell migration and invasion in MB cells remains to be determined.
Deregulated patterns of MCM expression were detected in both dysplasia and malignancy of various tissues/organs and the deregulations were regarded as an early event in carcinogenesis (Freeman et al., 1999; Tachibana et al., 2005; Williams and Stoeber, 2007) . It was demonstrated that MCM expression was associated with several clinicopathological parameters and also with patients' survivals Williams and Stoeber, 2007) . To date, most studies have focused on MCM2 expression alone. A high level of MCM2 proteins was linked to advanced stages of breast cancer, non-small-cell lung carcinoma, esophageal squamous cell carcinoma, colorectal cancer, gliomas and urothelial carcinoma (Ramnath et al., 2001; Wharton et al., 2001; Rodins et al., 2002; Gonzalez et al., 2003; Kato et al., 2003; Korkolopoulou et al., 2005; Scott et al., 2005; Hanna-Morris et al., 2009) . The aberrant expression of MCM2 was also correlated with poor prognosis in patients (Meng et al., 2001; Ramnath et al., 2001; Wharton et al., 2001; Rodins et al., 2002; Korkolopoulou et al., 2005) . For other MCMs, overexpression of MCM7 was associated with relapse, local invasion, a worse tumor grade and poor survival in prostate cancer patients (Ren et al., 2006) . Elevated protein expression of MCM6 was also linked to poor prognosis for mantle To construct the MB tissue microarray (TMA), formalin-fixed and paraffin-embedded tissue blocks were retrieved from the tissue banks and tumor areas were identified on the corresponding hematoxylin and eosin-stained slides. The tissue blocks were cored and transferred to a recipient block using a Tissue Microarrayer (Beecher Instruments, Silver Spring, MD, USA). Each core is 0.6 mm in diameter and spaced 0.7-0.8 mm apart. The TMA slides were deparaffinized with xylene and then rehydrated with a series of ethanol with decreasing concentration. Microwave-assisted antigen retrieval with 10 mM citrate buffer (pH 6) was performed. A 0.03% hydrogen peroxide/methanol buffer was used to block endogenous peroxidase activity. After rinsing with Tris-buffered saline, the slides were incubated with 5% normal rabbit serum for blocking and then with primary antibodies at the indicated dilution in the text for 32 min at 37 1C in a Ventana autostainer (Ventana). Horseradish peroxidase-labeled polymer conjugated to goat anti-mouse/rabbit secondary antibody was used to recognize the bound antibody. The sections were developed with 3,3 0 -diaminobenzidine for 10 min, counterstained with hematoxylin, and mounted with Immuno-mount (Shandon, Pittsburgh, PA, USA). (b) Results of immunohistochemistry for MCM2, MCM3, MCM7 and Ki67 are tabulated. Immunopositivity was defined as the percentage of nuclear stained MB cells in tissue sections, which were 425% for MCM2, MCM3 and MCM7 and 45% for Ki67. Shown in parentheses are the percentages of MB cases with immunopositivity in four histological subtypes. (c, d) Kaplan-Meier survival curves with log-rank test was used to determine the relationships of MCM2, MCM3, MCM7 and Ki67 immunopositivity with overall survival (c) and disease-free survival (d) in MB patients. The censored patients are shown with solid ovals for immunopositive cases and crosses for immunonegative cases. Clinical follow-up data of 20 MB patients were analyzed, as no survival data are available for the others. cell lymphoma patients (Schrader et al., 2005) . In this study, we simultaneously examined the expression of multiple MCMs in MB. Interestingly, we observed differential expression patterns of various MCMs in MB even though they were generally considered to function as a ring-shaped heterohexameric complex containing one of each subunit MCM2-7 . We found that some cases showed overexpression of one or two MCMs, but no significant change of other MCM expression in MB. There were o50% of our MB samples with concordant expression of MCM2, MCM3 and MCM7 using immunohistochemistry. Moreover, only expression of MCM3, but not the others, showed a prognostic value and the overexpression was associated with poor survival in MB patients. In addition, we found that siRNA knockdown of MCM3 induced G0/G1 cell arrest with reduction of cyclin A expression, whereas the MCM2-and MCM7-knocked-down cells arrested at G2/M with an increase of cyclin A expression. These findings suggested the differential roles of these overexpressed MCMs in MB for cell cycle control with modulation of cyclin A expression. Interestingly, MCM2 and MCM3 are phosphorylated by ATR (ataxia-telangiectasia-mutated-and Rad3-related) and ataxia-telangiectasia-mutated, respectively, whereas MCM7 interacts with Rad3-related-interacting protein in checkpoint activation for DNA damage response (Cortez et al., 2004) . These MCM modifications by ataxia-telangiectasia-mutated and Rad3-related might have functions unrelated to origin firing in DNA replication licensing as the phosphorylated MCMs are both chromatin-bound and in the cytosol (Shechter and Gautier, 2004) . Our finding of specific overexpression of MCM2, MCM3 and MCM7, but not the others, in MB may imply the significances of this DNA damage checkpoint and ataxia-telangiectasia-mutated/Rad3-related-mediated phosphorylations of MCMs in MB tumorigenesis. Recent studies have indicated that MCM proteins could be useful biomarkers reflecting the proliferating status of the cells in various cancers (Lei, 2005; Tachibana et al., 2005; Williams and Stoeber, 2007) . Combined assessment of Ki-67 and MCM expression revealed a subset of cancer cells that expressed MCMs, but not Ki67, in DNA replication-licensed but nonproliferating cells. These cells are competent to reenter the cell division cycle and reside in a G1 extended or arrested state (Todorov et al., 1994; Endl et al., 2001; Stoeber et al., 2001; Williams and Stoeber, 2007) . It was shown that increase of this cell population was significantly associated with high tumor grades in renal cell carcinoma, prostate cancer and oligodendroglioma (Dudderidge et al., 2005 (Dudderidge et al., , 2007 Wharton et al., 2007) and with tumor metastasis in colorectal cancer (Nishihara et al., 2008) . We also observed higher labeling indexes for MCM2, MCM3 and MCM7 than that for Ki67 in MB, indicating the presence of this licensed but nonproliferative MB cell population. Some MBs showed a high level of this cancer cell subset, whereas the others showed comparable MCMs and Ki67 labeling indexes, revealing two distinct groups of MB patients with different cancer behaviors probably related to prognosis. However, we are unable to identify any correlation with clinicopathological parameters in our study cohort.
Immunohistochemical data indicated that overexpression of these three MCMs was restricted to MB cells, but not to the adjacent nonproliferative normal neural cells, and the siRNA knockdowns in MB cells inhibited both anchorage-dependent and -independent growths with cell cycle arrest and apoptosis and reduced the migration and invasion capabilities. Therefore, targeting these MCMs potentially could be an effective cancerspecific therapeutic approach for MB patients. Although there is a small fraction of normal proliferative cells in various vital tissues/organs, it was shown that normal cells, at least L-02 normal liver cells, remained functional with no apoptosis and just merely showed delayed proliferation in response to inhibition of MCM2 expression (Feng et al., 2003) . When the therapeutic agents targeting MCMs are removed or metabolized, Figure 4 Effects of MCM2, MCM3 and MCM7 siRNA knockdowns on MB anchorage-dependent and -independent cell growths, cell cycle distribution and cyclins expression. (a) DAOY cells were seeded onto a 96-well plate and cultured for 4 days with transfection reagents alone (reagent control) or with scramble negative control RNA interference (control siRNA), MCM2 siRNA, MCM3 siRNA or MCM7 siRNA. MTT assay was performed after treatments for 4 days. Relative cell growths to the reagent control at day 4 are presented, with the cell growth for reagent control set as 1. (b) Flow cytometric histograms of propidium iodide-stained MB cells treated with transfection reagents alone or with control siRNA, MCM2 siRNA, MCM3 siRNA or MCM7 siRNA for 24 h (upper) and 48 h (lower). Ratios of G0/G1 to G2/M cell populations are presented. (c) Cyclin A, cyclin B, cyclin D, MCM2, MCM3, MCM7 and b-actin protein expression in the 24-h-treated cells were determined using western blot analysis. The siRNA-treated and control cells were lysed in lysis II buffer containing 0.125 M Tris-base, 1% NP-40, 2 mM EDTA, 20% glycerol, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 1 Â complete protease inhibitors cocktail and 1 mM PMSF, pH 7.5. Five 20-mg protein lysates were run onto 10-12.5% polyacrylamide gels with SDS and transferred onto polyvinylidene fluoride membranes. Primary antibodies were incubated with the membranes and recognized with horseradish peroxidase-conjugated secondary antibodies. ECL-Plus Western Blotting Detection Reagents (Amersham Biosciences, Piscataway, NJ, USA) were used to visualize the complexes. Bio-Rad Precision Plus protein size standard was used and the corresponding bands of size standard were marked in the films. (d) Representative dot plots of Annexin V staining on DAOY cells treated with MCM2, MCM3, MCM7 and control siRNAs for 48 h. Reagent control was included. The stained cells were analyzed by flow cytometry. (e) Results of soft agar cell growth assay are presented. The siRNA-treated and control DAOY cells were plated onto soft agar for 7 days and the cell growths were measured by AlamarBlue cell viability assay. Percentage difference in reduction of AlamarBlue between siRNA-treated and control cells were calculated and the cell growth for reagent control was set as 1. Student t-test was conducted to compare the relative cell growths between the MCM-knocked-down cells and the control siRNA-treated cells and P-values are presented. Two independent experiments were performed and three replicates were included for each treatment group in the MTT assay, flow cytometry and Annexin V staining, while six replicates were included in the soft agar growth assay. Columns represent means; bars represent s.d.
relicensing of origins could be reactivated in normal proliferative cells without interfering their functions or killing them, in contrast to the cancer cells that undergo cell cycle arrest and eventually apoptosis as we and others showed (Feng et al., 2003; Blow and Gillespie, 2008) . Furthermore, replication licensing is essential for cancer cell proliferation and they could not become resistant to the therapeutic agents targeting this system by using an alternative pathway (Blow and Gillespie, 2008) . Taken together, MCM2, MCM3 and MCM7 could be attractive anticancer targets for development of effective therapy for MB patients. In conclusion, MCM2, MCM3 and MCM7 expression were frequently deregulated in MB. Moreover, our data indicated that these MCMs showed differential roles in controls of MB cell growth with modulation of cyclin A expression. Finally, we provided evidences in supporting the functional roles of these MCMs beyond replication licensing and revealed the links of these MCMs with regulation of MB cell migration and invasion, probably through cdc42 and Rho activations. All these data enhance our understanding on MB tumorigenesis and facilitate the development of effective target-specific therapy for MB patients with high efficacy but minimal toxicity. 
Materials and methods
Tumor samples and cell lines
Microarray dataset
Microarray data of NC and MB (46 classic and 14 desmoplastic MBs with standardized multimodality treatments and 45-year post-operational follow-up) were obtained from publicly available databases: Human Gene Expression Index (http://zlab.bu. edu/HugeIndex/databases.htm, Haverty et al., 2002) and Cancer Program Data Set, Broad Institute (http:// www.broad.mit.edu/cgi-bin/cancer/datasets.cgi). All data were log2 transformed and median-centred per array for normalization. The normalized signal intensities of MCM2-MCM7 were compared between NC and MB using Mann-Whitney U-test. Kaplan-Meier survival analysis with log-rank test was performed to evaluate the significance of MCM gene expression in MB patients' survival.
Array-based CGH Genomic DNAs were extracted from four MB cell lines (D283, DAOY, ONS76 and D341) and eight primary MB samples and subjected to array-based CGH using Agilent whole human genome 44K CGH microarray (Agilent Technologies, Santa Clara, CA, USA) in accordance with the manufacturer's protocol. The data were analyzed using CGH Analytics 3.2.32 program (Agilent Technologies) with Z-score algorithm for detection of chromosomal aberrations.
Fluorescence in situ hybridization Dual-color fluorescence in situ hybridization analysis was performed to determine the copy number of MCM7 gene in 33 formalin-fixed and paraffin-embedded primary tumor tissue sections as previously described (Hui et al., 2005) . BAC clone RP11-143F21 (7q22.1) labeled with Spectrum-Orange-dUTP (Vysis, Downers Grove, IL, USA) was used as target probe for MCM7 gene and BAC clone RP11-111K18 (7p14.1) labeled with Spectrum-Green-dUTP was included as reference probe for the short arm of chromosome 7.
Reverse transcription-polymerase chain reaction Total RNA samples were reverse-transcribed using Moloneymurine-leukemia-virus reverse transcriptase and random hexamers (Applied Biosystems, Foster City, CA, USA). Primer sequences are presented in Supplementary Table S3 . PCR using SYBR Green PCR Master-Mix (Applied Biosystems) was monitored in real time with iCYCLER (Bio-Rad Laboratories, Hercules, CA, USA). Cycle thresholds (C T 's) of the genes of interest and ribosomal protein 3 were determined. Relative fold changes between the expression of the genes of interest in MB and NC samples were determined by the 2 À½DDCT method (Livak and Schmittgen, 2001 ).
Immunohistochemistry
A total of 73 primary MB (8 anaplastic, 3 large cell, 9 desmoplastic and 53 classic MB) cases were used in the tissue microarray. For controls, there were four NC samples from autopsies and seven nonmalignant brain tissues with temporal microdygensis, temporal sclerosis or brain chronic inflammation. The tissue microarray slides were immunostained with anti-MCM2 antibody (Abcam, Cambridge, UK) at 1:100 dilution, anti-MCM3 antibody (Cell Signaling, Danvers, MA, USA) at 1:70 dilution, anti-MCM7 antibody (Abnova, Taipei, Taiwan) at 1:300 dilution or MIB-1 antibody (Immunotech, Westbrook, ME, USA) at 1:500 dilution in Ventana autostainer (Ventana, Tucson, AZ, USA).
Cell growth assay DAOY or ONS76 was treated with 40 nM siRNA targeting MCM2, MCM3 or MCM7 using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) for 4 days. Scrambled Stealth negative control RNA interference (control siRNA; Invitrogen) was also used. The cell growth was determined using CellTiter 96 Non-Radioactive Cell Proliferation Assay in accordance with the manufacturer's protocol (Promega, Madison, WI, USA). Flow cytometry analysis DAOY cells were treated with siRNAs or transfection reagent alone for 24 and 48 h. The treated cells were fixed and stained with propidium iodide. At least 20 000 stained cells were analyzed using FACSAria (BD-Biosciences, Franklin Lakes, NJ, USA). Apoptotic cells were determined using FITC: Annexin V apoptosis detection assay (BD Biosciences).
Soft agar growth assay
One-week 96-well soft agar growth assay was performed as previously described (Ke et al., 2004) . A mixture of DAOY or ONS76 cell suspension (7 Â 10 3 cells), 2 Â the corresponding culture medium with 10% fetal bovine serum and 0.8% Bacto Agar Select (BD Biosciences) in the presence of 11.25 pmol of siRNA targeting MCM2/MCM3/MCM7 or control siRNA with FuGENE-HD transfection reagent (Roche, Basel, Switzerland) was sandwiched by two layers of 1.2% Bacto Agar Select with 2 Â the corresponding culture medium with 10% fetal bovine serum. Each treatment was conducted in sextuplicate. After 7 days, the growth was determined using Invitrogen AlamarBlue (Invitrogen) cell viability assay in accordance with the manufacturer's protocol. For HEK293, the cells were transfected with either pFL-MCM2-Bsd, pFL-MCM3-Bsd, pFL-MCM7-Bsd or empty vector (pTracer-CMV/Bsd).
Wound closure assay DAOY cells were seeded onto a six-well plate and treated with 40 nM siRNA targeting MCM2/MCM3/MCM7 or control siRNA using Lipofectamine 2000 transfection reagent (Invitrogen) for 2 days. A scratch was introduced in a confluent cell monolayer and the cells were cultured in medium supplemented with 1% fetal bovine serum. The images were captured after incubation for 0, 9 and 26 h and analyzed using Image J program (http://rsb.info.nih.gov/ij/index.html) to quantify the wound area. The pCMV-AC-MCM2 (Origene) was linearized by XhoI digestion and the blunt end was generated in the linearized plasmids by T4 DNA polymerase. Full-length cDNA of MCM2 was released from the plasmid by EcoRI digestion and then cloned into the EcoR I digested pTracer-CMV/Bsd that was linearized by XbaI digestion and the XbaI site was filled by blunt-end reaction using T4 DNA polymerase to generate pFL-MCM2-Bsd. For pFL-MCM3-Bsd, full-length cDNA of MCM3 was released from pCMV-XL5-MCM3 (Origene) by NotI and XbaI digestions and subcloned into pTracer-CMV/Bsd at NotI and XbaI sites. Full-length cDNA of MCM7 from pCMV-XL4-MCM7 (Origene) was subcloned into pTracer-CMV/Bsd at NotI site to generate pFL-MCM7-Bsd. Overexpression of MCM2, MCM3 and MCM7 in the transfected D384 were confirmed using RT-PCR analysis (Supplementary Materials, Figure S4 ). Two independent experiments were performed and three replicates were included for each treatment group in the WST-1 assay, Transwell migration and invasion assays. Student t-test was used. Columns represent means; bars represent s.d. Figure 7 Effects of MCM2, MCM3 and MCM7 siRNA knockdowns on F-actin polymerization for filopodia and stress fiber formations and on cdc42 and Rho activations. (a, b) The siRNA-treated DAOY and the controls were stained with tetramethyl rhodamine isothiocyanate-conjugated phalloidin and the images under fluorescence microscopy were captured. Representative images were presented (a). Arrows indicate filopodia and arrowheads indicate intense stress fibers. The filopodial cells (left) and the cells with intense stress fibers (right) were counted and the percentages of these cells in the cultures were presented (b). Student t-test was used and P-values were presented. Two independent experiments were performed and three replicates were included for each treatment group. Columns, means; bars, s.d. (c) Results of Cdc42 and Rho activation assays on the siRNA knock down DAOY cellsand reagent control cells. The GTP-bound cdc42 and Rho in the cell lysates were pulled down by PBD-PAK and RBD-Rhotekin, respectively, and recognized by anti-human cdc42/Rho antibodies in western blot analysis. The levels of total cdc42 and Rho in the lysates were also determined and the signals for b-actin were used as loading control. To control the assay, the lysates treated with GTPgS and GPD were used as positive and negative controls, respectively. with 10% fetal bovine serum. The cells without any siRNA treatment were included as reagent control. After 19 h, the migrated cells were stained with crystal violet and photographed. The stained cells were dissolved in 10% acetic acid and the absorbance at 560 nm was measured. Relative cell density was determined as the percentage difference in the absorbance relative to the reagent control. For Transwell invasion assay, the siRNA-treated cells and controls were seeded onto the upper chamber of a Transwell, similar to the above Transwell migration assay, except that the membrane of the Transwell was pre-coated with 2 mg per well Matrigel (BD Biosciences), 22 h being the incubation time. Transfected HEK293 and D384 with pFL-MCM2-Bsd, pFL-MCM3-Bsd, pFL-MCM7-Bsd or pTracer-CMV/Bsd were subjected to the assays similar to the above. For D384, the transfected cells were enriched by incubation in medium with 36 mg/ml blasticidin (IC50 ¼ 32 mg/ml) before the assays, because only 10% of the cells were transfected without enrichment and WST-1 assay was used to quantify the migrating/invading cells in the lower chamber.
F-actin staining F-actin was visualized by staining the siRNA-treated DAOY and the control (cells with control siRNA and cells with transfection reagent alone) cells with tetramethyl rhodamine isothiocyanate-conjugated phalloidin. Cells with F-actin-rich small spiky protrusions as filopodial cells and cells with intense stress fibers were counted.
Cdc42 and Rho activation assays
Cdc42 and Rho activation assays were performed with Rho and Cdc42 activation assay kits (Cell Biolabs, San Diego, CA, USA) in accordance with the manufacturer's recommended protocol. The siRNA-treated cells and controls (reagent control and negative control siRNA) were lysed with 1 Â assay/lysis buffer (Cell Biolabs). The levels of GTP-bound Cdc42 and Rho in the pull-down supernatants and the levels of total Cdc42 and Rho in the lysates were determined by western blot analysis using anti-human Cdc42/Rho antibodies.
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